TACT833

TACT833
Clinical data
Other names	TACT-833
Drug class	Monoamine transporter modulator; Serotonin 5-HT1B receptor modulator

TACT833 is a monoamine transporter modulator and serotonin 5-HT_1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.^[1]^[2] It is being developed by Tactogen.^[1]^[2] As of the first quarter of 2025, the drug is in the preclinical research stage of development.^[1]^[2]

References

^ ^a ^b ^c Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
^ ^a ^b ^c "Tactogen Inc – Pipeline". Tactogen Inc. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523.

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.